コンテンツにジャンプ

トップページ > グループ紹介 > ゲノムトランスレーショナルリサーチ分野（築地） > 業績

業績

2024年

  1. Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO Open. 2024 Apr 12;9(4):102981. doi: 10.1016/j.esmoop.2024.102981.
  2. Arakawa A, Tao K, Kohno T, Ogawa C. Cross-individual cancer transmission to children during the gestational and perinatal periods. Cancer Sci. 2024 Apr;115(4):1039-1047. doi: 10.1111/cas.16102. PMID: 38369705; PMCID: PMC11006992.

2023年

  1. Yoshida T, Yatabe Y, Kato K, Ishii G, Hamada A, Mano H, Sunami K, Yamamoto N, Kohno T. The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan. Cancer Biol Med. 2023 May 3:j.issn.2095-3941.2023.0036. doi: 10.20892/j.issn.2095-3941.2023.0036. 
  2. Tao K, Yamazaki F, Kubo T, Sunami K, Kumamoto T, Arakawa A, Sugiyama M, Watanabe Y, Nakajima M, Shirakawa N, Tanimura K, Koyama T, Hirata M, Sudo K, Tanabe N, Watanabe T, Yoshida T, Kitami M, Yoshida A, Yatabe Y, Nakano Y, Ohira M, Kamijo T, Nakazawa A, Kato M, Ichimura K, Kohno T, Yamamoto N, Hishiki T, Ichikawa H, Ogawa C. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. JCO Precis Oncol. 2023 Jul;7:e2200266. doi: 10.1200/PO.22.00266.

  3. Saito R, Kuroda T, Yoshida H, Sudo K, Saito M, Tanabe H, Takano H, Yamada K, Kiyokawa T, Yonemori K, Kato T, Okamoto A, Kohno T. Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma. Jpn J Clin Oncol. 53(9), 781-790, 2023. doi: 10.1093/jjco/hyad045.

2022年

  1. Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, Koya J, Saito Y, Tabata M, Yoshifuji K, Mizuno K, Miyagi-Maeshima A, Matsushita H, Sugiyama M, Ogawa C, Inamoto Y, Fukuda T, Sugano M, Yamauchi N, Minami Y, Hirata M, Yoshida T, Kohno T, Kohsaka S, Mano H, Shiraishi Y, Ogawa S, Izutsu K, Kataoka K. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022 Aug;113(8):2763-2777. doi: 10.1111/cas.15427.
  2. Nagai S, Nishihara H, Suzuki T, Nishio K, Taniguchi H, Tsuchihara K, Nakamura K, Takamatsu R, Ueno T, Aburatani H, Kohno T, Kohsaka S. Recommendations related to the analytical equivalence assessment of gene panel testing. Cancer Sci. 2022, doi: 10.1111/cas.15513.
  3. Tabata J, Nakaoku T, Araki M, Yoshino R, Kohsaka S, Otsuka A, Ikegami M, Ui A, Kanno SI, Miyoshi K, Matsumoto S, Sagae Y, Yasui A, Sekijima M, Mano H, Okuno Y, Okamoto A, Kohno T. Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis. Cancer Res. 2022, 82(20):3751-3762. doi: 10.1158/0008-5472.CAN-22-0834.
  4.  Seki Y, Yoshida T, Kohno T, Masuda K, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Kuwano K, Ohe Y. Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study. Respir Investig. 2022, 60(6):852-856. doi: 10.1016/j.resinv.2022.08.002.

雑誌論文（和文）

  1. 河野隆志. 全ゲノムシークエンス解析の臨床応用に向けた取り組み. 腫瘍内科. 29(1) 120-124, 2022.

  2. 河野隆志. 肺がんの全ゲノムシークエンス解析と臨床実装. 肺癌．62(1): 10-14, 2022.

  3. 額賀重成, 河野隆志. がんと遺伝子融合―Pan‒Cancer での治療をめざして―. 癌と化学療法, 49(10), 1030 - 1034, 2022.


2021年

  1. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T*, Ogawa C*. Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. N Engl J Med. 384(1):42-50, 2021. doi: 10.1056/NEJMoa2030391.

  2. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y*. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs. Thorac Cancer. 12 (5): 631-642, 2021. 

  3. Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 26(2):233-283, 2020.

  4. Takeyasu Y, Okuma H, Kojima Y, Nishikawa T, Maki Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Yoshida A, Yamamoto N, Yonemori K. Impact of ALK inhibitors in patients with ALK-rearranged nonlung solid tumors. JCO Precision Oncology, 5 756-766, 2021. DOI: 10.1200/PO.20.00383.

  5. Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Nosaki K, Kohno T, Tsuta K, Nomura S, Ikeno T, Wakabayashi M, Sato A, Matsumoto S, Goto K. Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. Lung Cancer. 2021 May;155:40-45. doi: 10.1016/j.lungcan.2021.03.002. 
  6. Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. 

  7. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol. 51(12):1757-1760, 2021. doi: 10.1093/jjco/hyab159.

2020年

  1. Kohno T, Tabata J, Nakaoku T. REToma: a cancer subtype with a shared driver oncogene (40th anniversary review article). Carcinogenesis, 41(2):123-129, 2020.

  2. Ito M, Fujiwara Y, Kubo T, Matsushita H, Kumamoto T, Suzuki T, Sunami K, Yamamoto N, Kohno T: Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. Front Oncol 10, 113, 2020.

  3. Watanabe S, Shimomura A, Kubo T, Sekimizu M, Seo T, Watanabe SI, Kawai A, Yamamoto N, Tamura K, Kohno T, Ichikawa H, Yoshida A. BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma. Mod Pathol. 33(9):1660-1668, 2020.

  4. Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Res Treat. 182(2):491-502, 2020.

  5. Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2020 Nov 29. doi: 10.1007/s10147-020-01831-6. 

雑誌論文（和文）

  1. 河野隆志. 保険診療で行う小児がんに対する遺伝子パネル検査. 小児科臨床 Vol.73 No.5, 0581-0586, 2020.

  2. 中奥敬史、田畑潤哉、河野隆志．REToma：RET遺伝子異常をもつ癌腫．分子呼吸器病．24(1): 1-5, 2020.

  3. 河野隆志. 保険診療で行う小児がんに対する遺伝子パネル検査. 小児科臨床. 73(5): 581-586, 2020.

  4. 河野隆志. TOP-GEARプロジェクトとNCCオンコパネルの保険収載. 医学の歩み. 27(9): 958-964, 2020.

 

2019年

  1. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T*. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110(4):1480-1490, 2019.

  2. Ikemura S, Yasuda H*, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K*, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 116(20):10025-10030, 2019.

  3. Wirth LJ, Kohno T (co-first author), Udagawa H, Ishii G, Ebata KB, Tuch B, Zhu EY, Nguyen M, Smith S, Hanson LM, Burkhard　MR, Cable L, Blake JF, Condroski KR, Brandhuber BJ, Andrews S, Rothenberg SM*, Goto K* (2019). Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in RET-altered cancer patients. JCO Prec Oncol, 2019, DOI: 10.1200/PO.19.00189.

  4. Mizuno T, Fujiwara Y, Yoshida K, Kohno T, Ohe Y. Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib. J Thorac Oncol. 14(5):e106-e108, 2019.

  5. Kuno I, Yoshida H, Kohno T, Ochiai A, Kato T. Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis. Gynecol Oncol Rep. 28:50-53, 2019.

  6. Kurozumi K, Nakano Y, Ishida J, Tanaka T, Doi M, Hirato J, Yoshida A, Washio K, Shimada A, Kohno T, Ichimura K, Yanai H, Date I. High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene. Brain Tumor Pathol. 36(3):121-128, 2019.

  7. Nakano Y, Tomiyama A, Kohno T, Yoshida A, Yamasaki K, Ozawa T, Fukuoka K, Fukushima H, Inoue T, Hara J, Sakamoto H, Ichimura K. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma. Brain Tumor Pathol. 2019 Jan;36(1):14-19.

  8. Suzuki A, Onodera K, Matsui K, Seki M, Esumi H, Soga T, Sugano S, Kohno T, Suzuki Y, Tsuchihara K. Characterization of cancer omics and drug perturbations in panels of lung cancer cells. Sci Rep. 9(1):19529, 2019.
  9. Seki M, Katsumata E, Suzuki A, Sereewattanawoot S, Sakamoto Y, Mizushima-Sugano J, Sugano S, Kohno T, Frith MC, Tsuchihara K, Suzuki Y. Evaluation and application of RNA-Seq by MinION. DNA Res. 26(1):55-65, 2019.

  10. Tsurubuchi T, Nakano Y, Hirato J, Yoshida A, Muroi A, Sakamoto N, Alexander Z, Matsuda M, Ishikawa E, Kohno T, Yoshioka T, Honda-Kitahara M, Ichimura K, Yamamoto T, Matsumura A. Subependymal giant cell astrocytoma harboring a PRRC2B-ALK fusion: A case report. Pediatr Blood Cancer. 66(12):e27995, 2019.

雑誌論文（和文）

  1. 河野隆志. 遺伝子パネル検査でみえるDNA修復欠損と発がん機構. がん分子標的治療 Vol.17 No.1, 31-34, 2019.

  2. 河野隆志. 国立がん研究センター「TOP-GEARプロジェクト」の実際. 産婦人科の実際. 2019年03月号(68巻 03号).

  3. 柿島 裕樹, 福原 萌, 千木良 浩志, 時田 和也, 澁木 康雄, 北見 繭子, 久保 崇, 川村 公彦, 角南 久仁子, 松下 弘道. がんゲノム医療における臨床検査の運用に向けて. 日本染色体遺伝子検査学会雑誌 2019年5月 (37巻 1号)

  4. 久保崇. はじめてのがん遺伝子パネル検査　特別講義　がん遺伝子パネル検査レポートを読むための6項目-NCCオンコパネルとF1CDx. Cancer Board Square. 2019年07月号(5巻 2号).

  5. 市川 仁. はじめてのがん遺伝子パネル検査　特別講義　がん遺伝子パネル検査のキーワード. Cancer Board Square. 2019年07月号(5巻 2号).

2018年

  1. Kohno T. Implementation of "clinical sequencing" in cancer genome medicine in Japan. Cancer Sci. 109(3):507-512, 2018.

  2. Kato M, Nakamura H, Nagai M, Kubo T, Elzawahry A, Totoki Y, Tanabe Y, Furukawa E, Miyamoto J, Sakamoto H, Matsumoto S, Sunami K, Arai Y, Suzuki Y, Yoshida T, Tsuchihara K, Tamura K, Yamamoto N, Ichikawa H, Kohno T, Shibata T. A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med, 10(1):44, 2018.

  3. Itahashi K, Kondo S, Kubo T, Fujiwara Y, Kato M, Ichikawa H, Koyama T, Tokumasu R, Xu J, Huettner CS, Michelini VV, Parida L, Kohno T, Yamamoto N. Evaluating Clinical Genome Sequence Analysis by Watson for Genomics. Front Med (Lausanne). 5時30分5, 2018.

  4. Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun. 9(1):625, 2018.
  5. Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 8(2):310-314, 2018.
  6. Sereewattanawoot S, Suzuki A, Seki M, Sakamoto Y, Kohno T, Sugano S, Tsuchihara K, Suzuki Y. Identification of potential regulatory mutations using multi-omics analysis and haplotyping of lung adenocarcinoma cell lines. Sci Rep. 8(1):4926, 2018.

  7. Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y. Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Sci Rep. 8(1):3482, 2018.

雑誌論文（和文）

  1. 角南久仁子、河野隆志. NCCオンコパネルを用いたクリニカルシーケンス―TOP-GEARプロジェクトの実装化へ向けた取り組み―　腫瘍内科. 22 (5), 505-510, 2018.

  2. 久保崇、河野隆志.　臨床応用に向けた疾患クリニカルシーケンス解析 第5章 4. NCCオンコパネル検査システムとTOP-GEARプロジェクト.  遺伝子医学MOOK, 34: 148-154, 2018.

  3. 河野隆志. プレシジョン・メディシン – がんゲノム医療の実現に向けて. 今日の治療指針　2018年版.

  4. 河野隆志. 遺伝子パネル検査 - 意義付けの標準化やデータ利活用に向けて. 実験医学 36(15): 2482-2487, 2018.

2017年

  1. Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 5時42分-50, 2017.
  2. George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Petersen I, Jang SJ, Buttners R, Harris CC, Yokota J, Thomas RK, Kohno T. Genomic amplification of CD274 (PD-L1) in small cell lung cancer. Clin Cancer Res. 23(5):1220-1226, 2017.
  3. Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. Oncotarget. 8(8):12941-12952, 2017.
  4. Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto Y, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas. 46(3):335-340, 2017.
  5. Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, Yonemori K, Ohe Y, Watanabe SI, Kawai A, Kohno T, Kishimoto H, Ichikawa H, Hiraoka N. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 30:797-809, 2017.

  6. Suzuki A, Suzuki M, Mizushima-Sugano J, Frith MC, Makalowski W, Kohno T, Sugano S, Tsuchihara K, Suzuki Y. Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer. DNA Res. 24(6):585-596, 2017.

雑誌論文（和文）

  1. 河野隆志、角南久仁子. がんのゲノム医療 -進行がんの治療選択のためのクリニカルシーケンシング- Medical Science Digest (2017-2月号), 2017.
  2. 久保崇、河野隆志. パラフィン包埋標本を用いたがんクリニカルシークエンスの試み. 病理と臨床, 35: 653-659, 2017.
  3. 河野隆志. クリニカルシークエンスによるがんの遺伝子プロファイリング検査と知識ベースの役割. BioClinica, 32, 23-28, 2017.

2016年

  1. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer, 15:73, 2016
  2. Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y. Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. Lung Cancer, 93:77-81, 2016
  3. Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. Oncologist, 21時15分6-164, 2016
  4. Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, SaitoM, Nokihara H, Watanabe S, Ohe Y, Kohno T. Multiplex diagnosis of oncogenic fusion and MET exon skipping by molecular counting using formalin-fixed paraffin embedded lung adenocarcinoma tissues. J Thorac Oncol. 11時20分3-12, 2016
  5. Kamata T, Sunami K, Yoshida A, Shiraishi K, Furuta K, Shimada Y, Katai H,Watanabe S, Asamura H, Kohno T, Tsuta K. Frequent BRAF or EGFR mutations in ciliated muconodular papillary tumors of the lung. J Thorac Oncol. 11(2), 261-5, 2016

雑誌論文（和文）

  1. 角南 久仁子：がん診療における治療選択のためのクリニカルシーケンシング, 病理と臨床, 34巻臨時創刊号, p.311-316, 2016.

  2. 角南久仁子、河野隆志、市川仁. がん診療における治療選択のためのクリニカルシーケンシング～院内遺伝子検査ラボにおけるLaboratory Developing Test運用について～　病理と臨床　34巻臨時創刊号, 2016.

2015年以前

  1. Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome Biol, 16:66, 2015.
  2. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res, 4時15分6-164, 2015.
  3. Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, Ichikawa H, Kato M, Watanabe S, Yoshida T, Yokota J, Kohno T. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res, 75:2264-2271, 2015.
  4. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T. KIF5B-RET fusions in lung adenocarcinoma. Nat Med, 18時37分5-377, 2012.

雑誌論文（和文）

  1. 市川　仁：国内における臨床シークエンスの展開―オリジナル遺伝子パネルNCC oncopanelを用いたクリニカルシークエンシング．医学のあゆみ249：1139-1144, 2014.
ゲノムTR分野（築地）
主な研究内容
メンバー
業績
共同研究プロポーザル
お問い合わせ
プレスリリース
  • EPOC研究者一覧NEW